Amedisys (NASDAQ:AMED) Receives Neutral Rating from Cantor Fitzgerald

Cantor Fitzgerald restated their neutral rating on shares of Amedisys (NASDAQ:AMED – Free Report) in a report released on Thursday morning, Benzinga reports. The firm currently has a $101.00 price objective on the health services provider’s stock. Several other equities research analysts have also commented on the stock. StockNews.com started coverage on shares of Amedisys […]

Related Keywords

Canada ,United States ,Raymond James ,Banque Cantonale Vaudoise ,Mesirow Institutional Investment Management Inc ,Contravisory Investment Management Inc ,Home Health ,Cetera Trust Company ,Amedisys ,Amedisys Inc ,Amedisys Company Profile ,Royal Bank ,Cantor Fitzgerald ,Free Report ,Get Free Report ,Cantonale Vaudoise ,Investment Management ,Mesirow Institutional Investment Management ,Institutional Investment Management ,High Acuity ,Amedisys Daily ,Nasdaq Amed ,Amed ,Medical ,02343610 ,Reiterated Rating ,